565
Participants
Start Date
July 1, 2016
Primary Completion Date
August 1, 2019
Study Completion Date
December 27, 2022
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Docetaxel
Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
Chulalongkorn Hospital; Medical Oncology, Bangkok
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok
Chungnam National University Hospital, Daejeon
Kyungpook National University Medical Center, Daegu
CHIANG MAI UNI HOSPITAL; FACULTY OF MEDICINE; Medical Oncology unit, Chiang Mai
Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi, Kuala Lumpur
Chonnam National University Hwasun Hospital, Jeollanam-do
Hospital Sultan Ismail; Oncology, Johor Bahru
Sarawak General Hospital; Department of Radiotherapy, Oncology and Palliative care, Sarawak
Cancer Hospital Chinese Academy of Medical Sciences., Beijing
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital; Oncology Department, Beijing
Liaoning cancer Hospital & Institute, Shenyang
the First Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
National Cancer Centre; Medical Oncology, Singapore
Shanghai chest hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu Cancer Hospital, Nanjing
Changzhou First People's Hospital, Changzhou
Affiliated Hospital of Bengbu Medical College, Bengbu
The Affiliated Hospital of Medical College Qingdao University, Qingdao
Tianjin Medical University General Hospital, Tianjin
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital, Hangzhou
Zhejiang Cancer Hospital, Zhejiang
Second Affiliated Hospital of Third Military Medical University, Chongqing
Third Affiliated Hospital of Third Military Medical University, Chongqing
Henan Cancer Hospital, Zhengzhou
Guangdong General Hospital, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Sun Yet-sen University Cancer Center, Guangzhou
West China Hospital, Sichuan University, Chengdu
The First Affiliated Hospital of Xian Jiao Tong University, Xi'an
Korea University Guro Hospital, Seoul
Hoffmann-La Roche
INDUSTRY